AQP4 antibody serostatus: Is its luster being lost in the management and pathogenesis of NMO?

Neurology

Volumn 81, Issue 14, 2013, Pages 1186-1188

  Fujihara, Kazuo ^a   Sato, Douglas Kazutoshi ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4 ANTIBODY; BETA INTERFERON; ECULIZUMAB; FINGOLIMOD; NATALIZUMAB; RITUXIMAB;

CLINICAL FEATURE; DISEASE EXACERBATION; DRUG EFFICACY; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; IMMUNOASSAY; IMMUNOFLUORESCENCE; LONGITUDINALLY EXTENSIVE TRANSVERSE MYELITIS; MULTIPLE SCLEROSIS; MYELITIS; MYELOOPTIC NEUROPATHY; NEUROMYELITIS OPTICA SPECTRUM DISORDER; OPTIC NEURITIS; PATHOGENESIS; PRIORITY JOURNAL; SERODIAGNOSIS;

AQUAPORIN 4; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MYELITIS, TRANSVERSE; NEUROMYELITIS OPTICA; OPTIC NEURITIS;

EID: 84888364263     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182a6cc23     Document Type: Editorial

References (10)

1. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-2112. (Pubitemid 39626806)
2. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805-815. (Pubitemid 47238676)
3. Weinshenker BG, Wingerchuk DM, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006;59:566-569. (Pubitemid 43358081)
4. Fujihara K, Misu T, Nakashima I, et al. Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease. Clin Exp Neuroimmunol 2012;3:58-73.
5. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG assays. Neurology 2012;78:665-671.
6. Marignier R, Bernard-Valnet R, Giraudon P. Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity- dependent entity. Neurology Epub 2013 May 8.
7. Jiao Y, Fryer JP, Lennon VA, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology 2013;81:1197-1204.
8. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107-1114. (Pubitemid 29442132)
9. Gault F. De la Neuromyélite Optique Aiguë. Lyon: Thèsis Lyon: A. Rey; 1894.
10. Ketelslegers IA, Modderman PW, Vennegoor A, et al. Antibodies against aquaporin-4 in neuromyelitis optica: distinction between recurrent and monophasic patients. Mult Scler 2011;17:1527-1530.